Immunoglobulin News and Research

RSS

Encouraging in vitro results with SARS-CoV-2-spike-specific polyclonal antibody fragments

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated the potent neutralizing ability of a polyclonal equine antibody (Ab), FBR-002, against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), including Omicron.

28 Feb 2022

Immunity before and after the SARS-CoV-2 Omicron variant in South Africa

Researchers conducted a national epidemiological survey to determine the seropositivity against SARS-CoV-2 before the emergence of the novel Omicron variant of concern.

28 Feb 2022

Health events amongst pregnant females after COVID-19 vaccination

Researchers evidenced that mRNA-based COVID-19 vaccines are safe in pregnancy, with lower rates of significant AEFIs in pregnant women than non-pregnant females.

28 Feb 2022

The epidemiology of COVID-19 in Africa

A new study uses the Africa CDC generic protocol for obtaining COVID-19 seroprevalence data to understand the spread and epidemiology of SARS-CoV-2.

27 Feb 2022

Outcomes of SARS-Cov-2 infection in patients undergoing active anti-cancer treatment

Researchers demonstrated that irrespective of the type of ACT, SARS-CoV-2 infection rates in patients receiving ACT remained comparable to the general population.

25 Feb 2022

Protective immunity signatures provided by convalescent plasma for the development of COVID-19 antibody therapeutics

Researchers conducted a comprehensive and systematic analysis of functional SARS-CoV-2 antibody profiles in a controlled randomized trial of severe COVID-19 hospitalized individuals treated with COVID-19 CCP.

25 Feb 2022

Serological responses to heterologous COVID-19 mRNA vaccination in older individuals

Researchers assess the serological response to a real-world COVID-19 vaccination strategy in older individuals who resided in long-term care facilities.

24 Feb 2022

Antibody levels against SARS-CoV-2 spike protein up to 12 months after COVID-19 infection in non-vaccinated individuals

A recent study assessed the persistence of SARS-CoV-2 antibody five and 12 months post-infection in non-vaccinated patients.

24 Feb 2022

Edible egg-derived IgY antibodies against SARS-CoV-2 Omicron

A new study posted to the bioRxiv* preprint server reports on the development of anti-RBD immunoglobulin Y (IgY) antibodies from chicken eggs to block the binding of the viral RBD to human ACE2 receptors. This approach has several advantages since chicken egg-derived IgY can be edible and polyclonal can target multiple epitopes, enhancing neutralizing activity.

23 Feb 2022

Low risk of second allergic reaction after SARS-CoV-2 vaccination

In a recent investigation posted to the journal JAMA Internal Medicine,* researchers estimate the risk of a repeated allergic reaction to the second severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger ribonucleic acid (mRNA) vaccine dose in those with a history of allergic responses following the first dose by conducting a systematic review and meta-analysis.

22 Feb 2022

Pre-existing B-cell immunity against SARS-CoV-2 not detected in pre-pandemic samples

A recent study investigates samples solated from unexposed individuals pre-pandemic to determine the presence of pre-existing SARS-CoV-2 B-cell immunity.

22 Feb 2022

New approach for extensive screening of monoclonal antibody clones against multiple myeloma cells

Multiple myeloma (MM) is a largely incurable cancer of plasma cells with an extremely poor prognosis. However, investigators from Japan have recently found that a common component of amino acid transporters, CD98 heavy chain, represents an effective monoclonal antibody target in treating MM.

22 Feb 2022

Immunoglobulin News and Research

Encouraging in vitro results with SARS-CoV-2-spike-specific polyclonal antibody fragments

Immunity before and after the SARS-CoV-2 Omicron variant in South Africa

Health events amongst pregnant females after COVID-19 vaccination

The epidemiology of COVID-19 in Africa

Outcomes of SARS-Cov-2 infection in patients undergoing active anti-cancer treatment

Protective immunity signatures provided by convalescent plasma for the development of COVID-19 antibody therapeutics

Serological responses to heterologous COVID-19 mRNA vaccination in older individuals

Antibody levels against SARS-CoV-2 spike protein up to 12 months after COVID-19 infection in non-vaccinated individuals

Edible egg-derived IgY antibodies against SARS-CoV-2 Omicron

Low risk of second allergic reaction after SARS-CoV-2 vaccination

Pre-existing B-cell immunity against SARS-CoV-2 not detected in pre-pandemic samples

New approach for extensive screening of monoclonal antibody clones against multiple myeloma cells

Lung microbiome alterations and secondary-infections in lethal COVID-19

Study suggests anti-SARS-CoV-2 antibodies may persist lifelong post-infection

Using IgG antibody assay to Identify natural SARS-CoV-2 infection in vaccinees

Novel ACE2-blocking antibody protects against all SARS-CoV-2 VOCs

Study reports potently neutralizing mucosal IgA in saliva of BNT162b2 vaccine recipients

Mathematical model of host immune response to SARS-CoV-2 demonstrates that age-related risk factors increased viral load

Inhalable antibody fragments offer broad protection from SARS-CoV-2 variants

Mechanism of fatty-acid coupled adaptive immunity in SARS-CoV-2 revealed

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News